

DEC 28 2000

amount of transforming growth factor consisting of TGF- β_3 sufficient to effect said inhibition.

²
~~73~~. The method according to claim ¹~~72~~ wherein said TGF- β_3 is provided in an inactive form that is converted to an active form.

³
~~74~~. The method according to claim ¹~~72~~ wherein said TGF- β_3 is provided in a pharmaceutically acceptable carrier.

⁴
~~75~~. A method of reducing scarring during healing of a wound in a patient in need thereof comprising providing at the site of said wound an amount of transforming growth factor consisting essentially of TGF- β_3 sufficient to effect said reduction in scarring.

⁵
~~76~~. The method according to claim ⁴~~75~~ wherein said TGF- β_3 is provided at said site in an inactive form that is converted to an active form at said site.

⁶
~~77~~. The method according to claim ⁴~~75~~ wherein said TGF- β_3 is provided at said site in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

RECEIVED

DEC 27 2001

TECH CENTER 1600/2900

RECEIVED

DEC 28 2001

TECH CENTER 1600/2900

If Cont.
⁷
~~78~~. A method of inhibiting fibrosis in a patient in need thereof comprising providing said patient with an anti-fibrotic agent selected from the group consisting of an anti-TGF- β_1 , an anti-TGF- β_2 and an anti-PDGF antibody and an amount of transforming growth factor consisting essentially of TGF- β_3 sufficient to effect said inhibition.

⁸
~~79~~. The method according to claim ⁷~~78~~ wherein said TGF- β_3 is provided at said site in an inactive form that is converted to an active form at said site.

⁹
~~80~~. The method according to claim ⁷~~78~~ wherein said TGF- β_3 is provided at said site in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

¹⁰
~~81~~. A method of reducing scarring during healing of a wound in a patient in need thereof comprising providing said patient with an anti-fibrotic agent selected from the group consisting of an anti-TGF- β_1 , an anti-TGF β_2 and an anti-PDGF antibody and an amount of transforming growth factor consisting essentially of TGF- β_3 sufficient to effect said inhibition.